Therefore, metabolic pathways (OXPHOS, amino acids, and lipid metabolism), AR signaling, neuroendocrine metabolism, Myc, and epigenetics drive metabolic reprogramming in prostate cancer and PCSCs. This evidence concerns the gene AR and Familial prostate cancer.